利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.02 秒)

    Process for preparing primycin salts
    6.
    发明授权
    Process for preparing primycin salts 失效
    伯霉素盐的制备方法

    公开(公告)号：US4782141A

    公开(公告)日：1988-11-01

    申请号：US751624

    申请日：1985-07-02

    申请人： Gyula Dekany ,  Judit Frank

    发明人： Gyula Dekany ,  Judit Frank

    IPC分类号： C07K9/00 ,  A61K9/00 ,  A61K9/02 ,  A61K9/06 ,  A61K9/107 ,  A61K9/14 ,  A61K9/20 ,  A61K9/70 ,  A61K35/74 ,  A61K38/00 ,  C07H15/238 ,  C07H17/08 ,  C07K14/195 ,  C07K14/41 ,  C07H15/04

    CPC分类号： C07H17/08

    摘要： This invention relates to salts of primycin formed with an organic acid--preferably a C.sub.1-16 aliphatic carboxylic acid, a halogenated carboxylic acid, an aliphatic dicarboxylic acid, an aromatic carboxylic acid, a substituted aromatic carboxylic acid or an organic sulfonic acid--or an inorganic acid--preferably a hydrohalogenic acid.There is furtheron provided a process for the preparation of new primycin salts which comprises reacting a suspension of primycin sulfate formed with an aliphatic alcohol containing 1-4 carbon atoms with a barium salt.The new primycin salts of the present invention possess excellent antibiotic properties.

    摘要翻译： 本发明涉及用有机酸 - 优选C 1-16脂族羧酸，卤代羧酸，脂族二羧酸，芳族羧酸，取代的芳族羧酸或有机磺酸形成的伯霉素的盐或 - 无机酸 - 优选氢卤酸。 还提供了制备新的伯霉素盐的方法，其包括使形成的伯霉素硫酸盐与含有1-4个碳原子的脂肪醇的悬浮液与钡盐反应。 本发明的新的伯霉素盐具有优异的抗生素特性。

    Process for the preparation of quinoline-carboxylic acid derivatives
    7.
    发明授权
    Process for the preparation of quinoline-carboxylic acid derivatives 失效
    喹啉羧酸衍生物的制备方法

    公开(公告)号：US4935512A

    公开(公告)日：1990-06-19

    申请号：US273853

    申请日：1988-06-03

    申请人： Judit Frank ,  Klara Beres nee Palmai ,  Gabor Kulcsar

    发明人： Judit Frank ,  Klara Beres nee Palmai ,  Gabor Kulcsar

    IPC分类号： A61K31/495 ,  A61P31/04 ,  C07D215/56 ,  C07D215/58

    CPC分类号： C07D215/56

    摘要： The invention relates to a new and simple process for the preparation of quinoline-carboxylic acid derivatives of the general formula (I) ##STR1## as well as hydrates and therapeutically acceptable salts thereof. In the formula the meaning of the substituents is as follows:R is hydrogen atom or a formyl group,R.sup.1 is a hydrogen atom or a straight or branched chain alkyl group having 1 to 4 carbon atoms, which may be substituted by a hydroxyl group, a halogen atom or an amino group; or a CH.sub.3 --NH-group,R.sup.2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms.According to the invention the compound of the general formula (II) ##STR2## or an acid addition salt thereof is reacted with piperazine in dimethylformamide and--if desired--the compound of the general formula (III) ##STR3## thus obtained is subjected to an acidic or alkaline treatment, or is reacted advantageously with hydrazine or preferably with hydrazine-hydrate.

    摘要翻译： PCT No.PCT / HU87 / 00044 Sec。 371日期：1988年6月3日 102（e）日期1988年6月3日PCT提交1987年10月14日PCT公布。 出版物WO88 / 02748 日本时间1988年04月21日。本发明涉及一种制备通式（I）的喹啉羧酸衍生物的新的和简单的方法，其水合物及其可治疗的盐。 在该式中，取代基的含义如下：R是氢原子或甲酰基，R 1是氢原子或可被羟基取代的具有1至4个碳原子的直链或支链烷基， 卤原子或氨基; 或CH 3 -NH基，R 2为氢原子或碳原子数1〜4的烷基。 根据本发明，通式（II）的化合物或其酸加成盐与二甲基甲酰胺中的哌嗪反应，如果需要，将通式（III）的化合物（III） ）进行酸性或碱性处理，或有利地与肼反应或优选与肼水合物反应。

    Antimicrobial pharmaceutical composition
    9.
    发明授权
    Antimicrobial pharmaceutical composition 失效
    抗微生物药物组成

    公开(公告)号：US4904647A

    公开(公告)日：1990-02-27

    申请号：US222056

    申请日：1988-07-20

    申请人： Gabor Kulcsar ,  Judit Frank ,  Peter Sarkozy ,  Katalin Kaloy

    发明人： Gabor Kulcsar ,  Judit Frank ,  Peter Sarkozy ,  Katalin Kaloy

    IPC分类号： A61K31/47 ,  A61K31/4375 ,  A61K31/473 ,  A61K31/65 ,  A61P31/00 ,  A61P31/04

    CPC分类号： A61K31/65

    摘要： The invention relates to a synergistic, antimicrobial pharmaceutical composition containing 0.01 to 50% by weight of a quinolinecarboxylic acid derivative or a naphthyridinecarboxylic acid derivative of the formula (I), ##STR1## wherein X is carbon or nitrogen;R.sup.1 is hydrogen or fluorine;R.sup.2 is methyl, piperazino or methylpiperazino group; orR.sup.1 and R.sup.2 together are a methylenedioxy group; and 0.01 to 95% by weight of a tetracycline derivative of the formula (II), ##STR2## wherein R.sup.3 and R.sup.4 are hydrogen; orR.sup.3 and R.sup.4 together represent an additional chemical bond,in 20:1 to 1:50 ratio of the compound of the formula (I) to the compound of the formula (II), optionally in an admixture with an amount required to 100% by weight of an inert, solid or liquid carrier such as magnesium carbonate, magnesium stearate, starch, talc, cyclodextrine or water and other additives such as filling, disintegrating, sliding and emulsifying agents.